Clinical Trial Detail

NCT ID NCT03698994
Title Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

rhabdoid cancer

non-Hodgkin lymphoma

histiocytic and dendritic cell cancer

osteosarcoma

germ cell cancer

neuroblastoma

malignant glioma

medulloblastoma

sarcoma

Ewing sarcoma

brain ependymoma

Advanced Solid Tumor

central nervous system cancer

hepatoblastoma

rhabdomyosarcoma

neuroectodermal tumor

nephroblastoma

Therapies

Ulixertinib

Age Groups: child adult

Additional content available in CKB BOOST